COMBINATION TREATMENT WITH ETANERCEPT AND AN INTENSIVE SPA REHABILITATION PROGRAM IN ACTIVE ANKYLOSING SPONDYLITIS
|
|
- Lynn Johns
- 6 years ago
- Views:
Transcription
1 INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY Vol. 22, no. 4, (2009) COMBINATION TREATMENT WITH ETANERCEPT AND AN INTENSIVE SPA REHABILITATION PROGRAM IN ACTIVE ANKYLOSING SPONDYLITIS M. COLINA, G. CIANCIO, R. GARAVINP, M. CONTP, F. TROTTAandM. GOVONI Rheumatology Section, Department ofclinical andexperimental Medicine, University offerrara; 1Presidio di Medicina Fisica e Riabilitazione delle Terme di Castrocaro, Italy Received May 8, AcceptedSeptember 24, 2009 The aim of this study is to determine the effects of a combination treatment with etanercept and spa rehabilitation versus etanercept alone on function, disability and quality of life in a group of patients with active ankylosing spondylitis (AS). Sixty patients with AS underwent etanercept as suggested by ASAS/EULAR recommendations. As the clinical and laboratory conditions improved, 30 patients accepted the proposal of coupling the medical therapy with a 7-day rehabilitation program in a thermal baths centre; the remaining 30 subjects continued to take the biologic agent alone. The comparisons between the 2 groups were made after 3 and 6 months. The primary outcome was an improvement in BASFI. The secondary outcome was an improvement in the visual analogic scale of EuroQol (EQ 5Dvas). After 6 months a statistically significant improvement in BASFI (p < 0.05) and EQ-5D vas (p < 0.05) scores was observed in both groups. The mean change in EQ-5D vas value showed a statistically significant difference in favour of the combination therapy group versus the monotherapy group (22 vs 32, P < 0.05). A therapeutic regimen combining etanercept with an intensive rehabilitation program contributes to disability reduction and ameliorates quality of life for AS patients. Ankylosing spondylitis (AS) is a chronic, inflammatory disease predominantly affecting young men. It is found worldwide, but more often in Caucasians, and the prevalence is reported to be about 0.1 to 0.2% (1-2). A typical target of the disease is the axial skeleton, and in particular the sacroiliac joints. Some patients may also experience peripheral arthritis and/or extra-articular manifestations such as acute anterior uveitis (3). The disease is mainly characterized by reduced spinal mobility with stiffness and pain, leading to severe functional impairment, disability and poor quality of life (4). As required pharmacological and nonpharmacological therapy and advice from different health professionals is suggested. Pharmacological therapy has been based for many years on nonsteroidal anti-inflammatory drugs (NSAIDs) and disease modifying anti-rheumatic drugs (DMARDs), such as sulfasalazine and methotrexate, which have only shown some beneficial effect on peripheral arthritis (5-7). Anti-tumor necrosis factor-a (TNF-a) agents have changed the approach to treatment of AS patients (8-10). Among them, etanercept has proved effective in controlling painful symptoms, reducing disability and improving the quality of life (10). Despite this, physiotherapy is still important in the treatment ofthe disease and it is more effective when carried out in a supervised spa group setting (11). It Key words: ankylosing spondylitis, rehabilitation, etanercept, BASFL quality oflife Mailing address: Matteo Colina, MD Sezione di Reumatologia, Dipartimento di Medicina Clinica e Sperimentale Universita degli Studi di Ferrara, Azienda S. Anna, Corso della Giovecca, Ferrara, Italy Fax: teocolina@libero.it (2009) Copyright by BIOLIFE, s.a.s, This publication and/or article is for individual use only and may not be further reproduced without written permission from the copyright holder. Unauthorized reproduction may result in financial and other penalties
2 1126 M. COLINA ET AL. is well accepted that the strong effect of anti-tnfa agents in relieving pain and stiffness could play a crucial role in warranting a favourable background for an effective rehabilitation program in AS patients (12). The aim ofthis study is to compare and evaluate the effects of anti-tnfa agent etanercept and spa rehabilitation vs etanercept alone on function, disability and quality of life in a group of patients with active AS. MATERIALS AND METHODS We enrolled 60 patients consecutively referred to our Clinic between September 2006 and August 2007 with active AS, who underwent etanercept therapy. All patients satisfied the modified New York classification criteria for AS (13). Inclusion criteria to start anti- TNFa therapywere the following: previous NSAIDs therapy failure (given for at least 3 months), a Bath AS Functional Index (BASFI) 2': 4, persistently high markers ofinflammation and a global health visual analogic scale (VAS) score or a pain VAS score 2': 40 (on a scale of 100 mm), Etanercept was selfadministered by patients as a 25 mg dose subcutaneously twice weekly. When etanercept treatment began, the majority ofpatients initially refused the physical program due to discomfort and pain. However, after 2 months, as the clinical conditions improved, 30 patients accepted the proposal to couple the medical therapy with a 7-day intensive rehabilitation program in a thermal baths center, while the remaining 30 subjects continued the therapy with the biologic agent alone. This proportion was completely random and was not dependent on prior decision. The intensive rehabilitation program was conducted in a thermal baths center by expert physiotherapists under the supervision of a physiatrist and included: hydro-kinesitherapy sessions, respiratory fitness sessions, massotherapy, muscular strengthening exercises with active and passive kinesitherapy, postural education and education on home self-treatment (Table I). The evaluation of efficacy and comparison between the 2 groups was made after 3 and 6 months. The primary outcome measure was an improvement ofbasfi, while the secondary outcome measure was an improvement in the self-rating VAS scale (0-100) of the European quality of life (EuroQol) questionnaire (EQ-5Dvas). The BASFI and the EQ-5D vas score were administered at the beginning of etanercept therapy, at the beginning of the intensive spa therapy and after 3 and 6 months following the 7-day rehabilitation program. Peripheral joint involvement, as well as ocular and skin manifestations were also tabulated, and HLA-B27 was assessed. Descriptive data were expressed as mean ± standard deviation. Statistical analysis was carried out using the t-test for paired and unpaired data. RESULTS As far as demographic characteristics and disease activity indices at the baseline are concerned, Table II shows that the two groups were homogeneous. Notably, we were dealing with long-standing diseases (with a mean duration of more than 8 years in both groups). Before starting etanercept, considering the two groups as a whole, mean BASDAI value was 7.3 ± 1.9 and mean BASFI value was 6.9 ± 1.6; mean EQ-5D vas value was 16 ± 4.8. After 2 months.of etanercepttherapy, the mean BASFI value had decreased to 5.6 ± 2.2 in the group who decided to couple the pharmacological therapy with the spa rehabilitation program and to 5.3 ± 2.5 in the group who continued the biologic agent alone. Quality of life also improved in all patients. The primary and secondary outcome measures at3 and 6 months are shown in Fig. 1. Three months after.,the intensive spa rehabilitation program a statistically significant improvement in BASFI scores was observed in both groups, without significant statistical differences between the 2 groups for the mean change in BASFI score. These results were confirmed after 6 months. After 3 and 6 months a statistically significant improvement in EQ-5Dvas scores was observed in both groups. In addition, the mean change in EQ-5Dvas value showed a statistically significant difference in favour of the combination therapy group both at 3 and 6 months. No patient experienced major adverse events due to etanercept. DISCUSSION Before the development of TNF-u antagonists, the treatment of AS was disappointing, leading to debilitating pain, spinal fusion and progressive disability. Because of the few pharmacological options, physical therapy has remained a mainstay for the treatment ofas in order to reduce pain, preserve spinal flexibility, prevent postural deformities and improve muscle strength. Although the TNF-a antagonism has dramatically changed the therapeutic scenario for patients with AS by providing symptom relief, retarding spinal inflammation and improving
3 Int. J. ImmunopatboI. Pbarmacol MONTHS FROM BA SELINE 5 MONTHS FROM II BASEUNE 8 MONTHS FROM BASEUNE _ ---'= = "-"-- BASEUNE I T w 80 P.tIe",. a BASFI : 2 69 m. G R EQ-5Dva s: ETA a 16 u p s $! I I BASI"I: BathAnkyJosingSpondJllilis l"unctionallndex; EQ-5Dvas: visualamjogicscale oferoqoi; mls: mol'llhs Fig. 1. Disposition ofthe patients in the study. Table I. Daily spa rehabilitation program. Morning Activities Description Session -Flex/extension ofthe trunk and lower limbs Individual Balneokinesitherapy -Trunk torsion and twist shoulderjoints Individual program ofexercise in thermal water -Controlled relaxing ofthe spine 30' Respiratory Kinesiterapy -Thoraco-pulrnonary mobilization Active - assisted exercises and respiratory -Chest and upper arms mobilization 30' exercises -Thoraco-pulmonary push and pull Functional Rehabilitation (passive and active mobilization: stretching and massage) -Cervical spine and upper trunk mobility -Exercises for lumbar and dorsal spine strength 40' Postural rehabilitation (exercises and advice on body balance) Afternoon -Postural correction therapy -Stategy for good body mechanics 40' -Education on selfcare Health meeting groups -Specific information from specialists in psychology, rheumatology and rehabilitation 60' quality of life, the role of physical therapy should not be considered obsolete. The importance of exercise in AS was also highlighted by the Authors of the Assessment of SpondyloArthritis international Society (ASAS)/European League Against Rheumatism (EULAR) recommendations for the management of AS, who included exercise therapy among their 10 recommendations (14). The
4 1128 M. COLINA ET AL. Table II. Demographics characteristics at the baseline. Monotherapy Combination therapy Number of patients Mean age (SD) 41.6 ± ± 7.2 Mean duration of disease (SD) 8.8 ± ±3.2 Peripheral arthritis (%) 6 (20%) 7 (22%) Skin involvement 1 1 Ocular involvement 1 0 HLAB27+(%) 24 (80%) 23 (78%) Mean age and mean duration ofdisease are expressedin years. SD: standard deviation strong effect of etanercept on inflammation and fatigue, in fact, surely plays a role in enhancing the physical performance ofas patients. It has also been demonstrated as important in increasing their motivational levels for physical therapy (15). To the best of our knowledge, this is the first study reporting the comparison between combination therapy with etanercept and an intensive spa rehabilitation program and etanercept therapy alone. In our studywe couldnot demonstrate an improvement of the functional index probably because we treated long-standing diseases and the functionality is strictly dependant on anatomical changes that had already occurred in the majority of our patients. For this reason it would be of huge interest to evaluate the efficacy of the combination therapy in patients with "early" axial spondyloarthropathies, in whom a greater improvement of the functionality index would be expected. For this reason, we believe that the "old" spa therapy is regaining credit in the midst of this "new", exciting, biologic era. It is worthy ofnote that we observed a significant beneficial effect of the combination therapy on quality of life, lasting up to 6 months after the intensive 7 day rehabilitation program. As we have shown, the association of etanercept and a spa rehabilitation program can induce a better quality of life in AS patients even in the short term. Unfortunately, the short observation period does not permit us to deduce the real effect that this therapeutic strategy can yield over the very long natural history of this disease and further studies with longer follow-up are needed. Our study did not.consider socio-economic aspects, since bothetanercept and spa rehabilitation are expensive for the national health system in Italy. This might represent a limitation requiring a cost! benefit evaluation. It is also worth underlining that the spa rehabilitation program did not begin at the same time as the therapy with etanercept because the majority of the patients refused the physical activity due to pain and stiffness. Consequently, we preferred to wait until a significant number ofpatients agreed to participate in the thermal rehabilitation program. In conclusion, our study confirms that combination treatment with etanercept and an intensive spa rehabilitation program contributes to disability reduction and ameliorates quality of life for AS patients. Combination treatment should be considered the best choice for the treatment ofas. ACKNOWLEDGEMENTS This work was supported by a grant of CARIFE in as part of the University of Ferrara sponsorship collaboration
5 Int. J. Immunopathol. Pharmacol REFERENCES 1. Gran JT, Husby G. The epidemiology of ankylosing spondylitis. Semin Arthritis Rheum 1993; 22: Will R, Edmunds L, Elswood J, et al. Is there sexual inequality in ankylosing spondylitis? A study of 498 women and 1,202 men. J Rheumatol1990; 17: Khan MA. Clinical features ofankylosing spondylitis. In: Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH, eds. Rheumatology, 3rd edn. Mosby, London 2003, Sieper J, Braun J, Rudwaleit M, et al. Ankylosing spondylitis: an overview. Ann Rheum Dis 2002; 61(S): Clegg DO, Reda DJ, Weisman MH, et al. Comparison of sulfasalazine and placebo in treatment of ankylosing spondylitis: a Depatments of Veteran Affairs cooperative study. Arthritis Rheum 1996; 39: Dougados M, van der Linden S, Leirisalo Repo M, et al. Sulfasalazine in the treatment of spondyloarthropathy: a randomized, multicenter, double-blind, placebo-controlled study. Arthritis Rheum 1995; 38: Roychowdhury B, Bintley-Bagot S, Bulgen DY, et al. Is methotrexate effective in ankylosing spondylitis? Rheumatology 2002; 41: Gorman JD, Sack KE, Davis JC Jr. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor a. N Engl J Med 2002; 346: Braun J, Brandt J, Listing J, et al. Treatment ofactive ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 2002; 359: Ca1inA, Dijkmans BA, Emery P, et al. Outcome ofa multi centre randomised clinical trial of etanercept to treat ankylosing spondylitis. Ann Rheum Dis 2004; 63: Dagfinrud H, Kvien TK, Hagen KB. The Cochrane review ofphysiotherapy interventions for ankylosing spondylitis. J Rheumato12005; 32: Lubrano E, D' Angelo S, Parson WJ, et al. Effects ofa combination treatment of an intensive rehabilitation program and etanercept in patients with ankylosing spondylitis: a pilot study. J Rheumatol 2006; 33: Van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modifications ofthe New York criteria. Arthritis Rheum 1984; 27: Zochling J, van der Heijde D, Burgos-Vargas R, et al. ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2006; 65: Dubey SG, Leeder J, Gaffney K. Physical therapy in anti- TNF treated patients with ankylosing spondylitis. Rheumatology 2008; 47:
ISPUB.COM. Effects Of Physical And Rehabilitative Treatment On Quality Of Life Of Ankylosing Spondylitis Patients
ISPUB.COM The Internet Journal of Orthopedic Surgery Volume 21 Number 2 Effects Of Physical And Rehabilitative Treatment On Quality Of Life Of Ankylosing Spondylitis Patients B Singh, A Upadhyay, M Garg,
More informationCertolizumab pegol (Cimzia) for the treatment of ankylosing spondylitis second or third line
Certolizumab pegol (Cimzia) for the treatment of ankylosing spondylitis second or third line August 2011 This technology summary is based on information available at the time of research and a limited
More informationScottish Medicines Consortium
Scottish Medicines Consortium etanercept 25mg vial of powder for subcutaneous injection (Enbrel ) (No. 212/05) Wyeth New indication: severe active ankylosing spondylitis inadequately controlled by conventional
More informationEffect of Infliximab Therapy in Functional Improvement in Patients with Ankylosing Spondylitis
Original article Effect of Infliximab Therapy in Functional 10.5005/jp-journals-10066-0003 Improvement in Patients with AS Effect of Infliximab Therapy in Functional Improvement in Patients with Ankylosing
More informationSustained efficacy and safety, including patient-reported outcomes, with etanercept treatment over 5 years in patients with ankylosing spondylitis
Sustained efficacy and safety, including patient-reported outcomes, with etanercept treatment over 5 years in patients with ankylosing spondylitis E. Martín-Mola 1, J. Sieper 2, M. Leirisalo-Repo 3, B.A.C.
More informationWhat is Axial Spondyloarthritis?
Physiotherapist Module 2 What is Axial Spondyloarthritis? How does it apply to physiotherapists? Claire Harris, Senior Physiotherapist, London North West Healthcare NHS Trust Susan Gurden, Advanced Physiotherapy
More informationThe Relationship Between Clinical Activity And Function In Ankylosing Spondylitis Patients
Bahrain Medical Bulletin, Vol.27, No. 3, September 2005 The Relationship Between Clinical Activity And Function In Ankylosing Spondylitis Patients Jane Kawar, MD* Hisham Al-Sayegh, MD* Objective: To assess
More informationadalimumab, 40mg/0.8mL, solution for injection (Humira ) SMC No. (858/13) AbbVie Ltd (previously part of Abbott)
adalimumab, 40mg/0.8mL, solution for injection (Humira ) SMC No. (858/13) AbbVie Ltd (previously part of Abbott) 08 March 2013 The Scottish Medicines Consortium (SMC) has completed its assessment of the
More informationShort term in-patient rehabilitation in axial spondyloarthritis - the results of a 2-week program performed in daily clinical practice
Eppeland et al. BMC Research Notes 2013, 6:185 RESEARCH ARTICLE Short term in-patient rehabilitation in axial spondyloarthritis - the results of a 2-week program performed in daily clinical practice Siv
More informationSpA non-radiografica: fase precoce di spondilite anchilosante o altro?
Rheumatology Department of Lucania, S. Carlo Hospital of Potenza and Madonna delle Grazie Hospital of Matera SpA non-radiografica: fase precoce di spondilite anchilosante o altro? Ignazio Olivieri Disclosures
More informationNonsurgical management of ankylosing spondylitis
Neurosurg Focus 24 (1):E5, 2008 JAYPAL REDDY SANGALA, M.D., M.CH., D.N.B., ELIAS DAKWAR, M.D., JUAN URIBE, M.D., AND FERNANDO VALE, M.D. Department of Neurological Surgery, University of South Florida,
More informationA mong the inflammatory rheumatic diseases
659 REVIEW Early referral recommendations for ankylosing spondylitis (including pre-radiographic and radiographic forms) in primary care J Sieper, M Rudwaleit... An earlier diagnosis of ankylosing spondylitis
More informationQuality indicators, guidelines and outcome measures in ankylosing spondylitis
Quality indicators, guidelines and outcome measures in ankylosing spondylitis J. Zochling, J. Braun Jane Zochling, MBBS, MMed (ClinEpi), PhD, Research Fellow, Menzies Research Institute, Hobart, Australia;
More informationGender differences in effectiveness of treatment in rheumatic diseases
Gender differences in effectiveness of treatment in rheumatic diseases Irene van der Horst-Bruinsma Associate Professor Rheumatology Center of Excellence of Axial Spondyloarthritis ARC/VU University Medical
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)
European Medicines Agency Pre-Authorisation Evaluation of Medicines for Human Use London, 23 April 2009 Doc. Ref. CPMP/EWP/4891/03 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON CLINICAL
More informationIndirect comparison of anti-tnf-α agents for active ankylosing spondylitis: mixed treatment comparison of randomised controlled trials
Indirect comparison of anti-tnf-α agents for active ankylosing spondylitis: mixed treatment comparison of randomised controlled trials T. Shu 1, G.H. Chen 2, L. Rong 1, F. Feng 1, B. Yang 1, R. Chen 1,
More information2016 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis. Online supplementary material
2016 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis Online supplementary material 1. Introduction A systematic literature review (SLR) was performed to inform the
More informationSCIENTIFIC DISCUSSION. London, 27 April 2006 Product name: HUMIRA/TRUDEXA Procedure number: EMEA/H/C/ /II/26
SCIENTIFIC DISCUSSION London, 27 April 2006 Product name: HUMIRA/TRUDEXA Procedure number: EMEA/H/C/481-482/II/26 3.1. Introduction Adalimumab is a recombinant human immunoglobulin (IgG 1 ) monoclonal
More informationTreatment of ankylosing spondylitis: focus on etanercept
REVIEW Treatment of ankylosing spondylitis: focus on etanercept Tracy Frech University of Utah, Division of Rheumatology, UT, USA Abstract: Ankylosing spondylitis is a chronic inflammatory condition which
More informationPerformance of the Ankylosing Spondylitis Disease Activity Score (ASDAS) in patients under biological therapies
Performance of the Ankylosing Spondylitis Disease Activity Score (ASDAS) in patients under biological therapies 1. Introduction The Ankylosing Spondylitis Disease Activity Score (ASDAS) is a new instrument
More informationAnkylosing spondylitis: diagnosis and management
CONTINUING PROFESSIONAL CPDDEVELOPMENT Page 60 Ankylosing spondylitis multiple choice questionnaire Page 61 Read Patience Fordjour s practice profile on respiratory infection Page 62 Guidelines on how
More informationGuideline on the Clinical Investigation of Medicinal Products for the Treatment of Axial Spondyloarthritis
12 October 2017 EMA/CPMP/EWP/4891/03 Rev.1 Committee for Medicinal Products for Human Use (CHMP) Guideline on the Clinical Investigation of Medicinal Products for the Treatment of Axial Draft agreed by
More informationSCIENTIFIC DISCUSSION
European Medicines Agency London, 20 September 2007 Product name: Remicade Procedure number: EMEA/H/C/240/II/95 SCIENTIFIC DISCUSSION 7 Westferry Circus, Canary Wharf, London, E14 4HB, UK Tel. (44-20)
More informationNonradiographic axial spondyloarthritis: clinical and therapeutic relevance
Ghosh and Ruderman Arthritis Research & Therapy (2017) 19:286 DOI 10.1186/s13075-017-1493-8 REVIEW Nonradiographic axial spondyloarthritis: clinical and therapeutic relevance Nilasha Ghosh and Eric M.
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Overview. Adalimumab, etanercept and infliximab for ankylosing spondylitis
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Overview Adalimumab, etanercept and infliximab for ankylosing spondylitis The overview is written by members of the Institute s team of technical analysts.
More informationThe Impact of Pain on the Functionality and Mobility of Patients with Ankylosing Spondylitis and the Role of Physiotherapy in their Rehabilitation
January-April 2018 Volume 11 Issue 1 Page45 Original Article The Impact of Pain on the Functionality and Mobility of Patients with Ankylosing Spondylitis and the Role of Physiotherapy in their Rehabilitation
More informationAssessment of Pulmonary Function Test (Pft) In Patients of Ankylosing Spondylitis
IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-issn: 2279-0853, p-issn: 2279-0861.Volume 16, Issue 8 Ver. X (Aug. 2017), PP 63-68 www.iosrjournals.org Assessment of Pulmonary Function Test (Pft)
More informationAxial Spondyloarthritis. Doug White, Rheumatologist Waikato Hospital
Axial Spondyloarthritis Doug White, Rheumatologist Waikato Hospital Disclosures Presentations / Consulting Abbott Laboratories AbbVie MSD Novartis Roche Clinical Trials Abbott Laboratories AbbVie Actelion
More informationOriginal Article Six-month home-based exercise and supervised training in patients with ankylosing spondylitis
Int J Clin Exp Med 2016;9(3):6635-6641 www.ijcem.com /ISSN:1940-5901/IJCEM0019104 Original Article Six-month home-based exercise and supervised training in patients with ankylosing spondylitis Hengying
More informationAnkylosing spondylitis functional and activity indices in clinical practice
Journal of Medicine and Life Vol. 7, Issue 1, JanuaryMarch 2014, pp.7883 Ankylosing spondylitis functional and activity indices in clinical practice Popescu C* **, Trandafir M*, Bădică AM*, Morar F*, Predeţeanu
More informationGolimumab, compared to placebo, significantly improved symptoms in adults with active nonradiographic
golimumab 50mg/0.5mL solution for injection in pre-filled pen or syringe and 100mg/mL solution for injection in pre-filled pen (Simponi ) SMC No. (1124/16) Merck Sharp & Dohme Limited 8 January 2016 The
More informationDisease Characteristics of Filipino Ankylosing Spondylitis Patients in Metro Manila Rheumatology Clinics
Philippine Journal of Internal Medicine Original Paper Disease Characteristics of Filipino Ankylosing Spondylitis Patients in Metro Manila Rheumatology Clinics Ma. Lucila Dianongco, M.D.*; Marc Gregory
More informationAnti-TNF-α Therapy for Ankylosing Spondylitis
Original Article Clinics in Orthopedic Surgery 2010;2:28-33 doi:10.4055/cios.2010.2.1.28 Anti-TNF-α Therapy for Ankylosing Spondylitis Jung-Hwan Son, MD, Sang-Won Cha, MD Department of Orthopedic Surgery,
More informationCover Page. The handle holds various files of this Leiden University dissertation
Cover Page The handle http://hdl.handle.net/1887/43590 holds various files of this Leiden University dissertation Author: Machado, Pedro Title: Health and imaging outcomes in axial spondyloarthritis Issue
More informationClinical and spinal radiographic outcome in axial spondyloarthritis Maas, Fiona
University of Groningen Clinical and spinal radiographic outcome in axial spondyloarthritis Maas, Fiona IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish
More information2004 Health Press Ltd.
... Ankylosing spondylitis Maxime Dougados MD Professor of Rheumatology Hôpital Cochin René Descartes University Paris, France Désirée van der Heijde MD PhD Professor of Rheumatology University Hospital
More informationConcept of Spondyloarthritis (SpA)
Concept of Spondyloarthritis (SpA) Spondyloarthritis: Characteristic Parameters Used for Diagnosis I Symptoms Inflammatory back pain Imaging Lab ESR/CRP Patient s history Good response to NSAIDs Spondyloarthritis-Characteristic
More informationSpondyloarthritis: Practice. New Concepts in. Epidemiology and Clinical
New Concepts in Spondyloarthritis: Epidemiology and Clinical Practice Atul Deodhar MD Professor of Medicine Oregon Health & Science University Portland, OR Northwest Rheumatism Society, Seattle, April
More informationINFLIXIMAB Remicade (infliximab), Inflectra (infliximab-dyyb), Renflexis (infliximab-abda)
RATIONALE FOR INCLUSION IN PA PROGRAM Background Remicade, Renflexis and Inflectra are tumor necrosis factor (TNFα) blockers. Tumor necrosis factor is an endogenous protein that regulates a number of physiologic
More informationAn Observational Descriptive Cross-Sectional Study of 200 Iraqi Adult Patients with Ankylosing Spondylitis: Analysis of Ocular Manifestations
An Observational Descriptive Cross-Sectional Study of 200 Iraqi Adult Patients with Ankylosing Spondylitis: Analysis of Ocular Manifestations Khudair Al-Bedri 1 Najah K. Mohammad Al-Quriashi 2 Faiq I.
More informationReview. Physiotherapy and rehabilitation in ankylosing spondylitis: is it still the mainstay of management in the era of biologics?
Physiotherapy and rehabilitation in ankylosing spondylitis: is it still the mainstay of management in the era of biologics? Ankylosing spondylitis is a systemic inflammatory disease characterized by involvement
More informationClinical and spinal radiographic outcome in axial spondyloarthritis Maas, Fiona
University of Groningen Clinical and spinal radiographic outcome in axial spondyloarthritis Maas, Fiona IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Proposed Health Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Proposed Health Technology Appraisal Secukinumab for treating ankylosing spondylitis after inadequate response to non-steroidal anti-inflammatory drugs
More informationCover Page. The handle holds various files of this Leiden University dissertation.
Cover Page The handle http://hdl.handle.net/1887/957 holds various files of this Leiden University dissertation. Author: Berg, Rosaline van den Title: Spondyloarthritis : recognition, imaging, treatment
More informationT he spondyloarthritides (SpA) comprise five subtypes:
1305 EXTENDED REPORT Magnetic resonance imaging of the spine and the sacroiliac joints in ankylosing spondylitis and undifferentiated spondyloarthritis during treatment with etanercept M Rudwaleit*, X
More informationCurrent Concept of Spondyloarthritis: Special Emphasis on Early Referral and Diagnosis
DOI 10.1007/s11926-012-0274-2 SERONEGATIVE ARTHRITIS (MA KHAN, SECTION EDITOR) Current Concept of Spondyloarthritis: Special Emphasis on Early Referral and Diagnosis Salih Ozgocmen & Muhammad Asim Khan
More informationEtanercept in the treatment of ankylosing spondylitis: A systematic review and meta-analysis
EXPERIMENTAL AND THERAPEUTIC MEDICINE 8: 1585-1592, 2014 Etanercept in the treatment of ankylosing spondylitis: A systematic review and meta-analysis YA-FEI LIU, HUI DONG, SHENG-HAO TU, CUI-HONG ZHENG,
More informationGolimumab: a novel anti-tumor necrosis factor
Golimumab: a novel anti-tumor necrosis factor Rossini M, De Vita S, Ferri C, et al. Biol Ther. 2013. This slide deck represents the opinions of the authors, and not necessarily the opinions of the publisher
More informationWhy is this important for you? Types of arthritis. Information for the public Published: 28 February 2017 nice.org.uk
Spondyloarthritis in over 16s: diagnosis and management Information for the public Published: 28 February 2017 nice.org.uk Spondyloarthritis: the care you should expect This information explains the care
More informationClinical Policy: Etanercept (Enbrel) Reference Number: PA.CP.PHAR.250 Effective Date: 01/18 Last Review Date: 08/17 Line of Business: Medicaid
Clinical Policy: (Enbrel) Reference Number: PA.CP.PHAR.250 Effective Date: 01/18 Last Review Date: 08/17 Line of Business: Medicaid Coding Implications Revision Log Description (Enbrel ) is tumor necrosis
More informationPrimary Results Citation 2
Table S1. Adalimumab clinical trials 1 ClinicalTrials.gov Rheumatoid Arthritis 3 NCT00195663 Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PREMIER study. A multicenter, randomized, double-blind clinical
More informationSerum sclerostin as a possible biomarker in ankylosing spondylitis: a casecontrol
Serum sclerostin as a possible biomarker in ankylosing spondylitis: a casecontrol study Fabio Massimo Perrotta 1, MD, Fulvia Ceccarelli 2, MD, PhD, Cristiana Barbati 2, PhD, Tania Colasanti 2, PhD, Antonia
More informationClinical Policy: Certolizumab (Cimzia) Reference Number: PA.CP.PHAR.247 Effective Date: 01/18 Last Review Date: 08/17 Line of Business: Medicaid
Clinical Policy: (Cimzia) Reference Number: PA.CP.PHAR.247 Effective Date: 01/18 Last Review Date: 08/17 Line of Business: Medicaid Coding Implications Revision Log Description (Cimzia ) is a tumor necrosis
More informationARTHRITIS ADVISORY COMMITTEE MEETING
ARTHRITIS ADVISORY COMMITTEE MEETING July 23, 2013 sbla 125057/323: adalimumab for the treatment of Active non-radiographic axial spondyloarthritis in adults with objective signs of inflammation by elevated
More informationChapter 2. Overview of ankylosing spondylitis
Chapter 2 Overview of ankylosing spondylitis The concept and classification of spondyloarthritis The term spondyloarthritis (SpA) comprises AS, reactive arthritis, arthritis/spondylitis associated with
More informationTHE BATH ANKYLOSING SPONDYLITIS PATIENT GLOBAL SCORE (BAS-G)
British Journal of Rheumatology 1996;35:66-71 THE BATH ANKYLOSING SPONDYLITIS PATIENT GLOBAL SCORE (BAS-G) S. D. JONES, A. STEINER,* S. L. GARRETT and A. CALIN Royal National Hospital for Rheumatic Diseases,
More informationaxial spondyloarthritis including ankylosing spondylitis
1 What is spondyloarthritis? Spondyloarthritis is a general term that describes a number of types of inflammatory arthritis which share many articular and extra-articular features. Conditions which fall
More informationBRIEF REPORT. Denis Poddubnyy, 1 Hildrun Haibel, 1 J urgen Braun, 2 Martin Rudwaleit, 3 and Joachim Sieper 1
ARTHRITIS & RHEUMATOLOGY Vol. 67, No. 9, September 2015, pp 2369 2375 DOI 10.1002/art.39225 VC 2015, American College of Rheumatology BRIEF REPORT Clinical Course Over Two Years in Patients With Early
More information5/4/2018. Outcome Measures in Spondyloarthritis. Learning Objectives. Outcome Measures Clinical Outcome Assessments
Outcome Measures in Spondyloarthritis Marina N Magrey MD Associate Professor Case Western Reserve University School of Medicine at MetroHealth Medical Center Learning Objectives What are outcome measures
More informationGrigorios T. Sakellariou, 1 Athanasios D. Anastasilakis, 2 Ilias Bisbinas, 3 Anastasios Gketsos, 4 and Charalampos Berberidis 1. 1.
ISRN Rheumatology Volume 2013, Article ID 907085, 4 pages http://dx.doi.org/10.1155/2013/907085 Clinical Study Efficacy of Anti-TNF Agents as Adjunctive Therapy for Knee Synovitis Refractory to Disease-Modifying
More informationSpondyloarthropathies: Disease Perception Limits Market
Spondyloarthropathies: Disease Perception Limits Market Psoriatic arthritis and ankylosing spondylitis form part of the group of diseases known as the spondyloarthropathies. Psoriatic arthritis is a form
More informationCoverage Criteria: Express Scripts, Inc. monograph dated 12/15/ months or as otherwise noted by indication
BENEFIT DESCRIPTION AND LIMITATIONS OF COVERAGE ITEM: PRODUCT LINES: COVERED UNDER: DESCRIPTION: CPT/HCPCS Code: Company Supplying: Setting: Kineret (anakinra subcutaneous injection) Commercial HMO/PPO/CDHP
More informationIdentification of Psoriatic Arthritis and Ankylosing Spondylitis Early Detection to Facilitate Appropriate Care
Identification of Psoriatic Arthritis and Ankylosing Spondylitis Early Detection to Facilitate Appropriate Care Joy Schechtman D.O. Professor Midwestern University 64C-1876207 Disclosures None 3 64C-1876207
More information2010 Annual Meeting of the Canadian Rheumatology Association February 3 to 6, Quebec City, Quebec. Copyright. Not for Sale or Commercial Distribution
21 Annual Meeting of the Canadian Rheumatology Association February 3 to 6, Quebec City, Quebec Copyright In February 21, Quebec City hosted the annual meeting of the Canadian Rheumatology Association
More informationAnkylosing spondylitis (Bechterew's Disease) [Name of Writer] [Name of Institute]
Ankylosing spondylitis 1 Running Head: ANKYLOSING SPONDYLITIS Ankylosing spondylitis (Bechterew's Disease) [Name of Writer] [Name of Institute] Ankylosing spondylitis 2 Ankylosing spondylitis (Bechterew's
More informationThe effect of two golimumab doses on radiographic progression in ankylosing spondylitis: results through 4 years of the GO-RAISE trial
Handling editor Tore K Kvien 1 Department of Rheumatology, Rheumazentrum Ruhrgebiet, Herne, Germany 2 Department of Radiology, Charité Medical School, Berlin, Germany 3 Division of Arthritis & Rheumatic
More informationINTRODUCTION THE SPINE WHAT HAPPENS
INTRODUCTION Ankylosing spondylitis or AS, is a form of arthritis that affects the spine, and can also affect other joints. It causes inflammation of the spinal joints (vertebrae) that can lead to severe,
More informationGender Differences in Clinical Features and Anti-TNF Agent Use in Korean Ankylosing Spondylitis Patients
Journal of Rheumatic Diseases Vol. 19, No. 3, June, 2012 http://dx.doi.org/10.4078/jrd.2012.19.3.132 Original Article Gender Differences in Clinical Features and Anti-TNF Agent Use in Korean Ankylosing
More informationOpen Access. Kayseri Turkey. Keywords: Rheumatoid arthritis, ankylosing spondylitis, recommendations, agreement, physiatrist.
The Open Rheumatology Journal, 2012, 6, 1-5 1 Open Access Agreement of Turkish Physiatrists with the Assessment in Spondyloarthritis International Society and the European League Against Rheumatism Recommendations
More informationHeel pain in spondyloarthritis: results of a cross-sectional study of 275 patients
Heel pain in spondyloarthritis: results of a cross-sectional study of 275 patients E. Koumakis, L. Gossec, M. Elhai, V. Burki, A. Durnez, I. Fabreguet, M. Meyer, J. Payet, F. Roure, S. Paternotte, M. Dougados
More informationAmor B, Kahan A, Dougados M, et al. Sulfasalazine and ankylosing spondylitis. Ann Intern Med 1984;101:878.
Chapter 12 References Amor B, Kahan A, Dougados M, et al. Sulfasalazine and ankylosing spondylitis. Ann Intern Med 1984;101:878. Amor B, Dougados M, Listrat V, et al. Are classification criteria for spondylarthropathy
More informationKey words: rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, treatment access
6, 21...,.,..,..,. - (RA) -,. (AS) (PsA). (Disease-modifying antirheumatic drugs, DMARDs). DMARDs 21. - RA, AS PsA. 21. RA, DMARDs. Leflunomide (Arava)., RA Methotrexate Leflunomid. DMARDs - 5 29. - RA
More informationDr Tracey Kain. Associate Professor Ed Gane
Associate Professor Ed Gane New Zealand Liver Transplant Unit Auckland Dr Tracey Kain Consultant Rheumatologist Grace Orthopaedic Centre Tauranga Hospital Tauranga 7:00-7:55 Abbvie Breakfast Session 1.
More informationDo HLA-B27 positive patients differ from HLA-B27 negative patients in clinical presentation
Do HLA-B27 positive patients differ from HLA-B27 negative patients in clinical presentation and imaging? Results from the DESIR cohort of patients with recent onset axial spondyloarthritis Ho Yin Chung
More informationAnja Weiß 1*, In-Ho Song 2, Hildrun Haibel 2, Joachim Listing 1 and Joachim Sieper 1,2
Weiß et al. Arthritis Research & Therapy 2014, 16:R35 RESEARCH ARTICLE Open Access Good correlation between changes in objective and subjective signs of inflammation in patients with short- but not long
More informationSwitching from infliximab or etanercept to adalimumab in resistant or intolerant patients with spondyloarthritis: a 4-year study
RHEUMATOLOGY Rheumatology 2010;49:1107 1111 doi:10.1093/rheumatology/keq008 Advance Access publication 11 March 2010 Original article Switching from infliximab or etanercept to adalimumab in resistant
More informationMultiple Technology Appraisal (MTA)
National Institute for Health and Care Excellence Multiple Technology Appraisal (MTA) TNF-alpha inhibitors for ankylosing spondylitis and axial spondyloarthritis without radiographic evidence of ankylosing
More informationAnkylosing spondylitis: Assessment and analysis of long-term outcome Ramiro, S.
UvA-DARE (Digital Academic Repository) Ankylosing spondylitis: Assessment and analysis of long-term outcome Ramiro, S. Link to publication Citation for published version (APA): Antunes da Cunha Oliveira
More informationLondon, 1 June 2006 Product name: REMICADE Procedure number: Remicade-H-240-II-73-AR SCIENTIFIC DISCUSSION 1/8
London, 1 June 2006 Product name: REMICADE Procedure number: Remicade-H-240-II-73-AR SCIENTIFIC DISCUSSION 1/8 1. Introduction Infliximab is a chimeric human-murine IgG1κ monoclonal antibody, which binds
More informationwww.fisiokinesiterapia.biz Peak onset between 20 and 30 years Form of spondyloarthritis (cause inflammation around site of ligament insertion into bone) and association with HLA-B27 Prevalence as high
More informationRheumatology Subcommittee of PTAC Meeting held 7 October (minutes for web publishing)
Rheumatology Subcommittee of PTAC Meeting held 7 October 2014 (minutes for web publishing) Rheumatology Subcommittee minutes are published in accordance with the Terms of Reference for the Pharmacology
More informationEligibility criteria for TNFi therapy in axspa: BASDAI vs ASDAS
Eligibility criteria for TNFi therapy in axspa: BASDAI vs ASDAS Abstract Background The Ankylosing Spondylitis Disease Activity Score (ASDAS) has been developed as a composite disease activity measure
More informationClinical and spinal radiographic outcome in axial spondyloarthritis Maas, Fiona
University of Groningen Clinical and spinal radiographic outcome in axial spondyloarthritis Maas, Fiona IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish
More informationSPARCC Abstracts and Publications
SPARCC Abstracts and Publications 2006 Papers 1. Siannis F, Farewell VT, Cook RJ, Schentag CT, Gladman DD. Clinical and radiological damage in psoriatic arthritis. Ann Rheum Dis online 2006;65 478-481
More informationSystematic review and analysis of evidences on clinical efficacy and cost-effectiveness of biological drugs for the treatment of
Systematic review and analysis of evidences on clinical efficacy and cost-effectiveness of biological drugs for the treatment of Ankylosing Spondylitis Márta Péntek Márta Péntek Systematic review and analysis
More informationOriginal article RHEUMATOLOGY. Rosaline van den Berg 1, Xenofon Baraliakos 2,Jürgen Braun 2 and Désirée van der Heijde 1. Abstract.
RHEUMATOLOGY Rheumatology 2012;51:1388 1396 doi:10.1093/rheumatology/kes066 Advance Access publication 17 April 2012 CLINICAL SCIENCE Original article First update of the current evidence for the management
More informationErelzi (etanercept) Frequently Asked Questions
Erelzi (etanercept) Frequently Asked Questions 1. What is the funding status of Erelzi (etanercept)? Effective December 21, 2017, Erelzi (etanercept) will be added to the Ontario Drug Benefit (ODB) Formulary
More informationA nkylosing spondylitis (AS) is a chronic, inflammatory. ASAS/EULAR recommendations for the management of ankylosing spondylitis EXTENDED REPORT
442 EXTENDED REPORT ASAS/EULAR recommendations for the management of ankylosing spondylitis J Zochling, D van der Heijde, R Burgos-Vargas, E Collantes, J C Davis Jr, B Dijkmans, M Dougados, P Géher, R
More informationImpact of Chronic Conditions on Health-Related Quality of Life
BURDEN OF ILLNESS Overview Impact of Chronic Conditions on Health-Related Quality of Life Chronic joint pain conditions have an important impact on health-related quality of life Note: a larger negative
More informationAssessment of fatigue in the management of patients with ankylosing spondylitis
Rheumatology Advance Access published September 16, 2003 Rheumatology 2003; 1 of 6 doi:10.1093/rheumatology/keg421, available online at www.rheumatology.oupjournals.org Assessment of fatigue in the management
More informationPerspective CME CME. Therapeutics for the treatment of spondyloarthritis: what, when and whom. Éric Toussirot*1,2 & Fabrice Michel1
Therapeutics for the treatment of spondyloarthritis: what, when and whom The therapeutic management of ankylosing spondylitis (AS) and spondyloarthritis includes AIDs and biological therapies (TNFa antagonists),
More informationThe Treatment of Axial Spondyloarthritis
This resource was organised and funded by AbbVie. It has been developed in collaboration with Claire Harris, Susan Gurden, Dr Jane Martindale, Claire Jeffries and NASS. For UK healthcare professionals
More informationHierarchy of Impairment of Spinal Mobility Measures in Ankylosing Spondylitis: Twelve-Year Data
Arthritis Care & Research Vol. 67, No. 11, November 2015, pp 1571 1577 DOI 10.1002/acr.22614 VC 2015, American College of Rheumatology ORIGINAL ARTICLE Hierarchy of Impairment of Spinal Mobility Measures
More informationA nkylosing spondylitis (AS) is an underrecognised,
1594 EXTENDED REPORT Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis A Calin, B A C Dijkmans, P Emery, M Hakala, J Kalden, M Leirisalo-Repo, E M Mola,
More informationCase Report The Efficacy and Safety of Rituximab in a Patient with Rheumatoid Spondylitis
Case Reports in Rheumatology Volume 2013, Article ID 792526, 4 pages http://dx.doi.org/10.1155/2013/792526 Case Report The Efficacy and Safety of Rituximab in a Patient with Rheumatoid Spondylitis Fenol
More informationMuhammad Haroon 1* Oliver FitzGerald 4. , Muddassar Ahmad 1, Muhammad Nouman Baig 2, Olivia Mason 3, John Rice 2 and
Haroon et al. Arthritis Research & Therapy (2018) 20:73 https://doi.org/10.1186/s13075-018-1565-4 RESEARCH ARTICLE Inflammatory back pain in psoriatic arthritis is significantly more responsive to corticosteroids
More informationFIBROMIALGIA: CLASSIFICAZIONE ED EPIDEMIOLOGIA DELLA SINDROME
FIBROMIALGIA: CLASSIFICAZIONE ED EPIDEMIOLOGIA DELLA SINDROME D.A. Filippini S.C. Reumatologia ASST Grande Ospedale Metropolitano Niguarda Milano MALATTIA DOLORE E RETE TERRITORIALE OSPEDALE NIGUARDA MILANO
More informationThe Incidence of Uveitis in Ankylosing Spondylitis Patients Undergoing Tumor Necrosis Factor Inhibiting Therapy in Korea
Journal of Rheumatic Diseases Vol. 22, No. 5, October, 2015 http://dx.doi.org/10.4078/jrd.2015.22.5.288 Original Article The Incidence of Uveitis in Ankylosing Spondylitis Patients Undergoing Tumor Necrosis
More informationSetting The setting was an outpatients department. The economic study was carried out in the UK.
Effectiveness and cost-effectiveness of three types of physiotherapy used to reduce chronic low back pain disability: a pragmatic randomized trial with economic evaluation Critchley D J, Ratcliffe J, Noonan
More information